A Phase 1 Multicenter Open-Label Study of CB-010 a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non Hodgkin Lymphoma
  • Age: Between 18 Year(s) - 90 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Histologically confirmed aggressive B-NHL
    2. Documented CD19+ disease
    3. At least 2 weeks since prior systemic non-investigational therapy at the time of start of lymphodepletion

You may not be eligible for this study if the following are true:

    1. History of prior therapy with an anti-CD19 targeting agent (Part A only)
    2. Active acute or chronic GvHD requiring therapy
    3. History of allogeneic stem cell transplantation



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.